[Basal-like breast cancer: a review].
Breast cancers of basal phenotype have been identified by molecular profiling and are associated with a poor prognosis. This review describes the morphological characteristics of these tumors and focuses on their profiling using immunohistochemistry: absence of detectable hormone receptors and HER2, expression of basal cytokeratins (CK5/6, CK14), myoepithelial markers (p63, smooth muscle actin) and HER1. This phenotype may be encountered in all histological types of breast cancer and is further divided into three subtypes according to prognosis and protein profiling. Pure basal and basal/myoepithelial subtypes have a poor prognosis in contrast to the myoepithelial subtype.
Treilleux
Isabelle
I
Service d'anatomie pathologique, centre Léon-Bérard, 69373 Lyon cedex 08, France. treilleu@lyon.fnclcc.fr
Morellon-Mialhe
Blandine
B
D001943:Breast Neoplasms / Q000737:chemistry / Q000145:classification / Q000401:mortality / Q000473:pathology*; D066246:ErbB Receptors / Q000032:analysis; D005260:Female; D006801:Humans; D007633:Keratins / Q000032:analysis; D009124:Muscle Proteins / Q000032:analysis; D009208:Myoepithelioma / Q000737:chemistry; D009363:Neoplasm Proteins / Q000032:analysis; D010641:Phenotype; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis
D066246:ErbB Receptors; D007633:Keratins; D009124:Muscle Proteins; D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; C512478:EGFR protein, human; C508053:ERBB2 protein, human